These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26256909)

  • 21. Treatment of intraventricular hemorrhage with intraventricular administration of recombinant tissue plasminogen activator A clinical study of 18 cases.
    Vereecken KK; Van Havenbergh T; De Beuckelaar W; Parizel PM; Jorens PG
    Clin Neurol Neurosurg; 2006 Jul; 108(5):451-5. PubMed ID: 16139422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature].
    Mele M; Mele A; La Torre PP; Cannone M
    G Ital Cardiol (Rome); 2014 Apr; 15(4):240-3. PubMed ID: 24873813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
    Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
    Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Very early mobilization in stroke patients treated with intravenous recombinant tissue plasminogen activator.
    Arnold SM; Dinkins M; Mooney LH; Freeman WD; Rawal B; Heckman MG; Davis OA
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1168-73. PubMed ID: 25869770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
    Wada T; Yasunaga H; Inokuchi R; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N
    J Neurol Sci; 2014 Oct; 345(1-2):106-11. PubMed ID: 25085762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue plasminogen activator for the treatment of parapneumonic effusions in pediatric patients.
    Israel EN; Blackmer AB
    Pharmacotherapy; 2014 May; 34(5):521-32. PubMed ID: 24390857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage.
    Ohkuma H; Parney I; Megyesi J; Ghahary A; Findlay JM
    J Neurosurg; 1999 Jun; 90(6):1105-14. PubMed ID: 10350259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).
    Kulkarni S; Rodriguez M; Lafuente A; Mateos P; Mehta J; Singhal S; Saso R; Tait D; Treleaven JG; Powles RL
    Bone Marrow Transplant; 1999 Apr; 23(8):803-7. PubMed ID: 10231143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resolution of hyphaema following intracameral injection of tenecteplase in a Stock Horse.
    Rendle DI; Hughes KJ
    Aust Vet J; 2013; 91(1-2):31-4. PubMed ID: 23356369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebral autoregulation dynamics in acute ischemic stroke after rtPA thrombolysis.
    Reinhard M; Wihler C; Roth M; Harloff A; Niesen WD; Timmer J; Weiller C; Hetzel A
    Cerebrovasc Dis; 2008; 26(2):147-55. PubMed ID: 18560218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.
    Romano JG; Smith EE; Liang L; Gardener H; Camp S; Shuey L; Cook A; Campo-Bustillo I; Khatri P; Bhatt DL; Fonarow GC; Sacco RL; Schwamm LH
    JAMA Neurol; 2015 Apr; 72(4):423-31. PubMed ID: 25642650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations.
    Seitz RJ; Hamzavi M; Junghans U; Ringleb PA; Schranz C; Siebler M
    Stroke; 2003 Aug; 34(8):1932-5. PubMed ID: 12829861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.
    Baziuk N; Fang T; Peyman GA; Gremillion CM
    Int Ophthalmol; 1991 Mar; 15(2):79-86. PubMed ID: 1902438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator.
    Fassbender K; Dempfle CE; Mielke O; Schwartz A; Daffertshofer M; Eschenfelder C; Dollman M; Hennerici M
    Stroke; 1999 Oct; 30(10):2101-4. PubMed ID: 10512913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic application of tissue plasminogen activator for fibrin reaction after cataract surgery.
    Ozveren F; Eltutar K
    J Cataract Refract Surg; 2004 Aug; 30(8):1727-31. PubMed ID: 15313298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
    Collatos C; Barton MH; Prasse KW; Moore JN
    J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy.
    Jauss M; Schütz HJ; Tanislav C; Misselwitz B; Rosenow F
    Eur J Neurol; 2010 Apr; 17(4):555-61. PubMed ID: 20218973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of recanalization and outcome in ischemic-stroke patients treated with recombinant tissue plasminogen activator.
    Wei XE; Zhao YW; Lu J; Li MH; Li WB; Zhou YJ; Li YH
    Acta Radiol; 2015 Sep; 56(9):1119-26. PubMed ID: 25182802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease in blood pressure after intravenous administration of urapidil during recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke.
    Bugnicourt JM; Duru C; Picard C; Godefroy O
    Clin Ther; 2008 Sep; 30(9):1675-80. PubMed ID: 18840373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis.
    Wardlaw JM; Sandercock PA; Berge E
    Stroke; 2003 Jun; 34(6):1437-42. PubMed ID: 12730560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.